Ninety-two percent of patients with HER2-positive (immunohistochemistry [IHC] 3+ or in situ hybridization-positive) invasive carcinoma (T > 1 cm or node-positive) treated with chemotherapy received adjuvant trastuzumab. Here, ERBB2 is linked to invasive carcinoma.